Skip to main content

DAVITA INC.

corporate_fare Company Profile

DAVITA INC.

DVA·NYSE·Industrial Applications And Services·CIK 0000927066

DaVita Inc. is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. The company is a comprehensive kidney care provider and has been a leader in clinical quality and innovation for more than 25 years. DaVita cares for patients at every stage and setting along their kidney health journey, from slowing the progression of kidney disease to helping support transplantation. This includes supporting patients at home, in their dialysis centers, in the hospital, and in skilled nursing facilities. The company's mission is to be the provider, partner, and employer of choice. Chronic kidney disease (CKD) has five stages, generally based on how well the kidneys filter waste and extra fluid from the blood. Higher stages of CKD correspond to progressing levels of kidney disease. Stage 1 CKD is the closest to healthy kidney function, while Stage 5 CKD indicates severe kidney damage.

DAVITA INC. (NYSE:DVA) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors DVA SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • CEO Javier Rodriguez Sells $14.5M in DaVita Stock
  • Officer/Director Javier Rodriguez Files Intent to Sell $8.2M in DaVita Stock Near 52-Week Highs
  • DaVita Secures $500M Term Loan from JPMorgan for Refinancing, Corporate Use
  • DaVita Secures $500M Incremental Term Loan for Refinancing and General Corporate Purposes
  • DaVita Reports Strong Q1 Earnings, Significant Share Repurchases, and Strategic Acquisition

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$13.64B
Net Income
$746.8M
Diluted EPS
$9.84
Op. Cash Flow
$1.89B
Free Cash Flow
$1.31B
Operating Income
$2.04B
Cash & Equivalents
$676.44M
Debt / Equity
0.00×
Net Margin
5.5%
Shares Outstanding
68.55M sh
Source: 10-K · filed 2026-02-11 · accession 0000927066-26-000012
Browse all tickers starting with D →
$231.23 -4.21% today
52-week range · as of 2026-06-17 $101 – $231.23
Market cap
$15.17B
Volume
625.5K (0.8× avg)
3-mo avg 784.5K
Live data · 2026-07-28 09:18 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed DVA - Latest Insights

DVA
Jun 17, 2026, 6:09 PM EDT
Filing Type: 4
Importance Score:
7
CEO Javier Rodriguez Sells $14.5M in DaVita Stock
Price at Filing: $210.58
Real-time Price: $231.23 info
Change: +$20.65 (+10%) info
Market Cap: $15.171B info
Sentiment: Negative
View Wiseek Article
DVA
Jun 16, 2026, 4:44 PM EDT
Filing Type: 144
Importance Score:
7
Officer/Director Javier Rodriguez Files Intent to Sell $8.2M in DaVita Stock Near 52-Week Highs
Price at Filing: $208.98
Real-time Price: $231.23 info
Change: +$22.25 (+11%) info
Market Cap: $15.171B info
Sentiment: Negative
View Wiseek Article
DVA
Jun 08, 2026, 4:43 PM EDT
Source: Wiseek News
Importance Score:
7
DaVita Secures $500M Term Loan from JPMorgan for Refinancing, Corporate Use
Price at Filing: $192.08
Real-time Price: $231.23 info
Change: +$39.15 (+20%) info
Market Cap: $15.171B info
Sentiment: Neutral
View Wiseek Article
DVA
Jun 08, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
7
DaVita Secures $500M Incremental Term Loan for Refinancing and General Corporate Purposes
Price at Filing: $192.08
Real-time Price: $231.23 info
Change: +$39.15 (+20%) info
Market Cap: $15.171B info
Sentiment: Neutral
View Wiseek Article
DVA
May 05, 2026, 5:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
DaVita Reports Strong Q1 Earnings, Significant Share Repurchases, and Strategic Acquisition
Price at Filing: $163.00
Real-time Price: $231.23 info
Change: +$68.23 (+42%) info
Market Cap: $15.171B info
Sentiment: Positive
View Wiseek Article
DVA
May 05, 2026, 4:21 PM EDT
Source: Reuters
Importance Score:
8
DaVita Boosts 2026 EPS Forecast on Strong Q1 Revenue and Earnings Beat
Price at Filing: $159.61
Real-time Price: $231.23 info
Change: +$71.62 (+45%) info
Market Cap: $15.171B info
Sentiment: Positive
View Wiseek Article
DVA
May 05, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
DaVita Reports Strong Q1 Results, Raises Full-Year Guidance, and Announces Significant Share Repurchases
Price at Filing: $162.00
Real-time Price: $231.23 info
Change: +$69.23 (+43%) info
Market Cap: $15.171B info
Sentiment: Positive
View Wiseek Article
DVA
Apr 02, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
8
Potential 100% Drug Tariffs Weigh on DaVita Shares; Company Launches PD Loss ML Model
Price at Filing: $146.40
Real-time Price: $231.23 info
Change: +$84.83 (+58%) info
Market Cap: $15.171B info
Sentiment: Negative
View Wiseek Article
DVA
Feb 11, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
DaVita Inc. Reports 2025 Financials with Profit Decline Amid Operational Headwinds and Ongoing Legal Challenges
Price at Filing: $144.27
Real-time Price: $231.23 info
Change: +$86.96 (+60%) info
Market Cap: $15.171B info
Sentiment: Negative
View Wiseek Article
DVA
Feb 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
DaVita Reports Strong Q4 & Full-Year 2025 Results, Exceeding Prior Year Performance and Initiates Positive 2026 Guidance
Price at Filing: $115.90
Real-time Price: $231.23 info
Change: +$115.33 (+100%) info
Market Cap: $15.171B info
Sentiment: Positive
View Wiseek Article